Also known as: PZA; NSC 366140; PD 115934
Pyrazoloacridine (PZA / NSC 366140) is a novel antineoplastic agent that intercalates DNA and inhibits both topoisomerase I and topoisomerase II, producing cytotoxic effects in cancer cells. Mediocon Inc manufactures this high-purity API at its GMP-certified facility in Aurangabad, Maharashtra, India. It has been investigated clinically for treatment of solid tumors.
| Parameter | Specification |
|---|---|
| CAS Number | 99009-20-8 |
| Molecular Formula | C17H13N3 |
| Molecular Weight | 263.31 g/mol |
| Grade | IP / BP / EP / USP |
| Category | Antineoplastic / Anticancer Agent |
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Batch No | PYR/24032026 |
| Mfg Date | MAR 2026 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Pyrazoloacridine — CAS 99009-20-8 (CAS 99009-20-8) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Pyrazoloacridine — CAS 99009-20-8 is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance